This page shows the latest EU news and features for those working in and with pharma, biotech and healthcare.
The Committee for Medicinal Products for Human Use (CHMP) has specifically recommended that the antibody-drug conjugate (ADC), which is already approved in the EU for certain lymphoma patients, be used ... The CHMP’s recommendation will now be reviewed
The EU regulator’s decision specifically applies to postmenopausal women and men with oestrogen receptor (ER) positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.
Anu Osinusi, vice president, clinical research for hepatitis, respiratory and emerging viruses at Gilead, said: “Despite lower levels of COVID-19 circulating in the EU than at the height of the ... The European Commission will now review the CHMP’s
Drug shortages have been an ongoing global issue. At the beginning of this year, the EU said it would be revising its pharmaceuticals law amid a growing number of antibiotic shortages.
The inflammatory skin disease is estimated to affect 4.4% of adults in the EU. ... The incidence of atopic dermatitis appears to have increased in recent decades, currently affecting an estimated 4.4% of adults in the EU.
The UK is set to rejoin the Horizon Europe research initiative through a bespoke new agreement with the EU. ... Following a discussion with EU Commission President, Ursula Von der Leyen, Sunak secured improved financial terms of association with Horizon
More from news
Approximately 148 fully matching, plus 2,464 partially matching documents found.
It is estimated that in the EU alone, AMR is associated with EUR 1.5 billion annually in healthcare costs and productivity losses.
Based on the results of PROpel trial, olaparib plus abiraterone has been approved the EU and several other countries for the treatment of patients with mCRPC.
The sea change had been building. EU drug regulators were placing increased emphasis on diversifying clinical trials through a fairer representation of gender and age groups.
the EU, UK and US that are reframing clinical trials.
CVs for application, submission and submission unit type CVs are relevant for the US, the EU and Japan. ... CV for category event submission type is relevant for Japan, and not for the US or the EU.
More from intelligence
Approximately 9 fully matching, plus 224 partially matching documents found.
awards, including Cannes Lions Healthcare Agency of the Year, PMEA EU Healthcare Agency of the Year and Creative Floor Most Awarded Agency.
Benjamin Rapp, regional president EU South at Ashfield Engage.
I look forward to working with the EFPIA Board and the wider community to achieve the shared goal of building a future EU health and innovation union.”. ... Realising that goal means EFPIA and its membership working with the EU and Member States to
Lugović joins from GOPA Com. Brussels, where she ran global campaigns for the European Commission across the EU, US, Africa and Asia. ... Prior to that, she headed the regional representation of South Serbia to the EU for a period of six years.
He added: “Over the coming months, my colleagues and I look forward to engaging with the EU Institutions and across Member States to discuss how we can work together to ensure ... that the EU remains an innovation leader and to build a healthier future
More from appointments
Approximately 2 fully matching, plus 68 partially matching documents found.
1 - European Environment Agency. Health. 2023. Available from https://www.eea.europa.eu/en/topics/at-a-glance/health [Accessed August 2023].
In this article for pharmaphorum's Oncology Deep Dive, Research Partnership reviews the market access opportunities and challenges encountered by CAR-Ts commercialised in the EU-4 and the UK (see
When the EU passed the PSD2 Law in 2019, giving approved and regulated third-party businesses the permission to connect to banks and make payments on consumers’ behalf, it kick started
Julie Cox reflects on our passion working in the rare disease space - helping to bring vital education to healthcare professionals, to benefit patients. There are more than 7000 rare diseases affecting an estimated 3.5 million people in the UK. 1.
Available at https://imi-paradigm.eu/survey/. Accessed November 2022. CDER Patient-Focused Drug Development. US Food and Drug Administration. ... Available at https://imi-paradigm.eu/wp-content/uploads/2020/09/PARADIGMD6.5_ PE-Sustainability-roadmap_FINAL
More from PMHub
Approximately 3 fully matching, plus 143 partially matching documents found.
No results were found
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...